Protein tyrosine phosphatase wedge domain peptide dimer for nervous system repair
AssigneeNervGen Pharma Corp.
InventorMatvey LUKASHEV
Life of this patent
Estimating the term…
Abstract
The disclosure relates to compositions and methods for nervous system repair. The compositions comprise a peptide that is a dimer, which comprises a first monomer covalently cross-linked with a second monomer, each monomer comprising a domain comprising an amino acid sequence derived from a cytoplasmic wedge domain of a receptor-type protein-tyrosine phosphatase (PTPR). The disclosure also relates to methods and compositions for treating diseases, disorders, and/or conditions associated with inhibition of nervous system repair by chondroitin sulfate proteoglycans (CSPG) or with suppressive effects of LAR family phosphatases, such as PTPRD, PTPRF, and PTPRS on neuro repair.
Claims59
A pharmaceutical composition comprising a peptide that is a dimer comprising a first monomer covalently cross-linked with a second monomer, each monomer comprising a domain comprising an amino acid sequence derived from a cytoplasmic wedge domain of a receptor-type protein-tyrosine phosphatase (PTPR), and wherein the mass ratio of the dimer to free monomer in the pharmaceutical composition is greater than 1:20.
A pharmaceutical agent for repairing the nervous system of a subject comprising a peptide dimer or pharmaceutically acceptable salt or solvate thereof, comprising two subunits, wherein each subunit comprises a peptide domain independently selected from receptor-type protein-tyrosine phosphatase (PTPR) wedge domains or variants having at least 70% homology thereto.
Dependencies are inferred from the claim text.